Eshallgo Inc. (Nasdaq: EHGO) Expands into Enterprise-Level AI Solutions: Targeting China's Rapidly Growing Intelligent Office Market
eShallgo, inc. Photo
New York, July 22, 2025 (GLOBE NEWSWIRE) -- SHANGHAI, July 22, 2025 — Eshallgo Inc. ('Eshallgo' or the 'Company') (Nasdaq: EHGO), a leading provider of integrated office solutions in China, today announced the official launch of its new business initiative focused on enterprise-level artificial intelligence (AI). The Company is leveraging its extensive office services infrastructure to enter the intelligent office AI segment through a fully integrated hardware-software platform, accelerating its presence in one of China's most dynamic digital transformation markets.
"With our official entry into the enterprise AI sector, Eshallgo is not just adapting to the future — we are building it," said Qiwei Miao, Chief Executive Officer of Eshallgo. "Our vision is to empower every enterprise with intelligent tools that create value through automation, security, and strategic insight. We believe this transformative growth will unlock significant long-term shareholder value."
Well- Positioned to Capture Value in a Multi-Billion Dollar Intelligent Office OpportunityAccording to data from the China Academy of Information and Communications Technology (CAICT), the total value of China's AI industry exceeded RMB 700 billion (~USD 96 billion) in 2025, with sustained annual growth above 20%. Within this, the enterprise-focused AI application market is expanding rapidly as businesses modernize office operations, streamline internal processes, and integrate AI-driven automation.
Zheshang Securities has said to be projecting that China's AI all-in-one device segment alone will grow from RMB 123.6 billion (~USD 17 billion) in 2025 to over RMB 520.8 billion (~USD 71 billion) by 2027, reflecting a compound annual growth rate (CAGR) exceeding 60%.
Globally, the market for AI in enterprise applications is expected to reach USD 200 billion by 2026, driven by increasing demand for intelligent workflow automation, secure knowledge management, and real-time decision support systems.
From Office Solutions to Smart Enterprise EnablementAs generative AI and large language models unlock new levels of functional intelligence, enterprises are under pressure to modernize legacy systems and accelerate digital transformation. Eshallgo, with years of experience in office integration and a nationwide enterprise customer base, is well-positioned to bring AI innovation directly into business environments.
The Company is launching a new family of scenario-specific AI solutions designed to address critical needs in enterprise environments, including:
Workflow automation and internal process optimization
Cost reduction through intelligent resource scheduling
Enhanced competitiveness via real-time analytics and smart decision tools
Robust data security and compliance enforcement
Smarter collaboration across hybrid and distributed teams
Enterprise AI Product Roadmap and Commercialization MilestoneEshallgo has partnered with leading domestic AI R&D teams to jointly develop enterprise-grade intelligent applications. The Company recently completed internal testing for its flagship enterprise-level AI platform, with a working demo now available for selected enterprise customers. This marks a key milestone on Eshallgo's path to commercializing intelligent office solutions tailored to the needs of China's enterprise clients.
Fulfilling Unmet Demand in Enterprise AI ScenariosThe initial product suite will include intelligent document management, automated task routing, smart procurement assistance, and cybersecurity-enhanced collaboration tools—all designed with modular architecture for integration into existing IT systems. Eshallgo's goal is to address previously underserved enterprise use cases where traditional software lacks real-time learning, adaptive workflows, or decision-making automation.
By focusing on scenario-based intelligence, Eshallgo aims to close a critical gap in China's enterprise AI landscape while creating value through efficiency, security, and agility in day-to-day business operations.
About eShallgo, Inc.eShallgo, Inc. (Nasdaq: EHGO) is a leading digital-first office solution provider headquartered in Shanghai, China. Through its integrated platform, the Company offers enterprise-grade hardware, printing services, software subscriptions, and technical support to small and medium-sized businesses across China. Leveraging data analytics and automation, eShallgo delivers cost-efficient and scalable solutions that empower businesses to digitize and streamline their back-office operations. For more information and real-time investor updates, please visit the Company's new investor portal at ir.eshallgo.com. Follow us on social media: LinkedIn, Facebook, and X.
Forward-Looking StatementsAll statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the SEC.
Investor and Media Contact:Tony SklarInvestor Relations – eShallgo, Inc.ir@eshallgo.com
About eShallgo, Inc.
eShallgo, Inc. (Nasdaq: EHGO) is a leading digital-first office solution provider headquartered in Shanghai, China. Through its integrated platform, the Company offers enterprise-grade hardware, printing services, software subscriptions, and technical support to small and medium-sized businesses across China. Leveraging data analytics and automation, eShallgo delivers cost-efficient and scalable solutions that empower businesses to digitize and streamline their back-office operations. For more information and real-time investor updates, please visit the Company's new investor portal at ir.eshallgo.com. Follow us on social media: LinkedIn, Facebook, and X.
Attachment
eShallgo, inc. Photo

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Top analyst warns on MicroStrategy results ahead of earnings
Top analyst warns on MicroStrategy results ahead of earnings originally appeared on TheStreet. Strategy (Nasdaq: MSTR), formerly MicroStrategy, is expected to report its financial results for the second quarter of 2025 after market hours on July 31. Strategy is the largest public corporate holder of Bitcoin. The company's Bitcoin stack of 628,791 coins is currently worth more than $74 billion. The firm's executive chairman and co-founder Michael Saylor urged anyone interested in Strategy or Bitcoin to join the earnings call at 5:00 p.m. EST. Zacks, the investment research firm, said it expected the Bitcoin treasury firm to report $112.15 million in Q2 revenue, hoping for a 0.64% rise year over year (YoY). Zacks expected Strategy's earnings per share (EPS) to record a loss of $0.12 per share. There are several factors, such as the Donald Trump administration's announcement to establish a strategic Bitcoin reserve, more regulatory clarity, Bitcoin's recent rally, and institutional and corporate adoption of the king coin, that go in favor of Strategy, the analysis mentioned. However, it added, "Bitcoin's inherent volatility, along with Strategy's stretched valuation, makes the MSTR stock a risky bet ahead of the second quarter of 2025."Let's look at the company's performance in Q1 2025. Strategy recorded a total revenue of $111.1 million, a decline of 3.6% YoY. In Q1, it reported a gross profit of $77.1 million, operating expenses of $6 billion, and loss from operations of $5.921 billion. As of March 31, it had cash and cash equivalents of $60.3 million. The MSTR stock, which closed at $395.04 on July 30, has grown more than 35% year-to-date (YTD). In contrast, Bitcoin, trading at $118,315.66 at press time, has only grown 25% YTD. Clearly, the leading Bitcoin treasury firm has outpaced Bitcoin itself — at least in YTD timeframe. Top analyst warns on MicroStrategy results ahead of earnings first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial
We recently compiled a list of CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), an area with limited options beyond invasive surgery. Recent data from the Phase 3 BOND-003 trial, presented in June 2025, revealed a 75.5% complete response rate, with 42.3% of patients maintaining that response at 24 months. Impressively, 97.3% remained free of progression to muscle-invasive disease, and 91.6% avoided cystectomy. The therapy was also well-tolerated, with no grade 3 or higher treatment-related adverse events reported. Cretostimogene stands out as a potential new standard for NMIBC, offering durable cancer control without surgery and preserving patients' quality of life. Its promising results have sparked interest in combining it with other therapies like pembrolizumab, further expanding its therapeutic potential. A healthcare specialist in the laboratory testing an Oncology-related product. CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint with trials targeting both BCG-naïve and previously treated patients. A Biologics License Application (BLA) is expected soon, supported by strong Phase 2 combination data published in Nature Medicine. The business is also offering expanded access programs, broadening patient reach before full regulatory approval. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
We recently compiled a list of Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company as a frontrunner in gene-targeted treatments and one of the best growth stocks in the biotech space. In July 2025, the company achieved a major milestone, a $100 million payment from Sarepta Therapeutics as part of a broader licensing and collaboration deal. The agreement includes clinical and preclinical RNAi candidates, offering the corporation up to $10 billion in potential milestone and royalty payments. This collaboration provides strong financial backing and external validation of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s RNAi technology. The business is making significant progress in the late-stage development of its cardiometabolic pipeline. In July 2025, the company initiated the Phase 3 YOSEMITE study for zodasiran in homozygous familial hypercholesterolemia. It also completed enrollment for several Phase 3 trials (SHASTA-3, SHASTA-4, and MUIR-3) evaluating plozasiran for severe hypertriglyceridemia and rare lipid disorders. Plozasiran's NDA has been accepted by the FDA, with a potential approval date of November 18, 2025. A biotechnologist in a lab setting, examining a sample of liquid for research and development. These developments underscore Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s momentum in bringing RNAi therapies to market. Positive Phase 3 results, including significant reductions in triglycerides and pancreatitis, highlight the strong efficacy of its treatments. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data